Nautilus Biotechnology Inc (NASDAQ: NAUT) has experienced a rise in its stock price by 9.45 compared to its previous closing price of 2.54. However, the company has seen a gain of 15.83% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-30 that Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Sujal Patel – Co-Founder & Chief Executive Officer Parag Mallick – Co-Founder & Chief Scientist Anna Mowry – Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Q1 2024 Earnings Conference Call.
Is It Worth Investing in Nautilus Biotechnology Inc (NASDAQ: NAUT) Right Now?
Moreover, the 36-month beta value for NAUT is 1.03. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NAUT is 57.03M and currently, short sellers hold a 1.95% of that float. On May 02, 2024, NAUT’s average trading volume was 79.70K shares.
NAUT’s Market Performance
NAUT stock saw an increase of 15.83% in the past week, with a monthly gain of 2.58% and a quarterly increase of 0.00%. The volatility ratio for the week is 12.45%, and the volatility levels for the last 30 days are 7.49% for Nautilus Biotechnology Inc (NAUT). The simple moving average for the past 20 days is 9.99% for NAUT’s stock, with a -4.55% simple moving average for the past 200 days.
Analysts’ Opinion of NAUT
Many brokerage firms have already submitted their reports for NAUT stocks, with Morgan Stanley repeating the rating for NAUT by listing it as a “Equal-Weight.” The predicted price for NAUT in the upcoming period, according to Morgan Stanley is $8 based on the research report published on January 06, 2022 of the previous year 2022.
Goldman gave a rating of “Neutral” to NAUT, setting the target price at $10 in the report published on August 04th of the previous year.
NAUT Trading at 5.20% from the 50-Day Moving Average
After a stumble in the market that brought NAUT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.22% of loss for the given period.
Volatility was left at 7.49%, however, over the last 30 days, the volatility rate increased by 12.45%, as shares surge +0.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.46% upper at present.
During the last 5 trading sessions, NAUT rose by +15.83%, which changed the moving average for the period of 200-days by -19.42% in comparison to the 20-day moving average, which settled at $2.53. In addition, Nautilus Biotechnology Inc saw -7.02% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NAUT starting from Patel Sujal M, who purchase 12,044 shares at the price of $2.84 back on Mar 11 ’24. After this action, Patel Sujal M now owns 10,064,488 shares of Nautilus Biotechnology Inc, valued at $34,216 using the latest closing price.
Patel Sujal M, the CEO, President, and Secretary of Nautilus Biotechnology Inc, purchase 2,430 shares at $2.99 during a trade that took place back on Mar 08 ’24, which means that Patel Sujal M is holding 10,052,444 shares at $7,262 based on the most recent closing price.
Stock Fundamentals for NAUT
Current profitability levels for the company are sitting at:
- -8.21 for the present operating margin
- 0.45 for the gross margin
The net margin for Nautilus Biotechnology Inc stands at -8.21. The total capital return value is set at -0.24. Equity return is now at value -24.38, with -21.26 for asset returns.
Based on Nautilus Biotechnology Inc (NAUT), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -1.65. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -21.79.
Currently, EBITDA for the company is -70.45 million with net debt to EBITDA at -0.11. When we switch over and look at the enterprise to sales, we see a ratio of 43.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.09.
Conclusion
To wrap up, the performance of Nautilus Biotechnology Inc (NAUT) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
